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Abstract. Phospholipase C (PLC) regulates a number of 
cellular behaviours including cell motility, cell transforma-
tion, differentiation and cell growth. PLC plays a regulatory 
role in cancer cells partly by acting as signalling intermedi-
ates for cytokines such as EGF and interleukins. The current 
study examined the expression of the PLC isozymes in human 
breast cancer and corresponding clinical relevance. Transcript 
levels of human PLC-α, -β1, -δ, -ε, and -γ1 in human breast 
cancer tissues were quantitatively determined by real-time 
PCR. Immunochemical staining was performed for PLC-δ. 
The clinical relevance was analysed with clinic pathological 
information. Mammary tissues widely expressed PLC-α, -β1, 
-δ, -ε, and -γ1. Significantly high levels of PLC -β1 and -ε 
were seen in breast cancer tissues in comparison with normal 
mammary gland tissues. PLC-γ1 however, showed marginally 
low levels in tumour tissues. No significant difference was 
seen in the expression of the PLC isozymes in tumours with 
lymph node metastases. Moderately and poorly differentiated 
breast tumours (grade 2 and grade 3) had significantly higher 
levels of PLC-γ1, compared with well differentiated tumours. 
High levels of PLC-δ were significantly correlated with a 
shorter disease-free survival. The altered expression of other 
isozymes had no correlation with the survival. It is concluded 
that mammary tissues differentially expressed PLC isozymes. 
These isozymes have certain implications in the disease devel-
opment and progression, with PLC-δ showing a significant 
correlation with shorter disease-free survival.
Introduction
Phospholipase C (PLC) is a type of membrane-associated 
enzymes consisting of thirteen mammalian PLC isozymes 
that are classified into five isotype groups (β, γ, δ, ε, ζ) based 
on their different structures (1). PLC-α also known as protein 
disulfide isomerase family A member 3 (PDIA3) interacts with 
calnexin and calreticulin to coordinate the folding of newly 
synthesised glycoprotein (2). According to gene sequence 
analysis studies, the major homology shared by different 
isozymes is presented in N-terminus with around 250 amino 
acid residues (3). The core enzyme of PLC is composed of 
a triosephosphate isomerase (TIM) barrel, a pleckstrin 
homology (PH) domain, four tandem EF hand domains, and 
a C2 domain (4). Specifically, an insert in the TIM barrel 
named the X-Y linker interrupts its function by occluding the 
active site. This can be remedied with the removal of the X-Y 
linker (5). Activated by all types of cell surface membrane 
receptors, PLC cleaves the phospholipid, phosphatidylinositol 
4, 5-bisphosphate (PIP2), into diacyl glycerol (DAG) and 
inositol 1, 4, 5-trisphosphate (IP3). These two products of 
the PLC-catalyzed reaction are important second messengers 
that control diverse cellular processes and are substrates for 
synthesis of other important signalling molecules (6).
As a phospholipid-hydrolyzing enzyme, PLC plays a signif-
icant role in the metabolism of inositol lipids. The bio active 
lipid mediators generated by PLC families are involved 
in a variety of cellular processes, which are implicated in 
promoting tumourigenesis through intercellular and extracel-
lular signalling pathways (7). Several studies have been carried 
out to detect the function of PLC subfamilies and the result 
demonstrated their essential role in regulating proliferation, 
invasion, and migration in cancer development (8-11). PLC-γ 
and PLC-ε work as oncogenes in regulating cell proliferation 
which is associated with Ras activities (12-14). Conversely, 
the deletion or downregulation of PLC-β and PLC-δ isoforms 
has been shown in human leukaemia (15,16). PLC-γ-mediated 
cell spreading and motility is achieved by its binding with the 
complex GPCR kinase interacting ARF-GAP 1 (GIT1) and 
the RAC1 and CDC42 GEF β-Pix, and subsequently leads to 
the activation of the RHO family GTPases CDC42 and RAC1. 
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Downregulation of PLC-γ1 expression severely impairs the 
activation of RAC, as well as cell invasion in breast cancer, 
glioblastoma and head and neck cancer cell lines (17).
The occurrence and development of breast cancer is related 
to aberrant signalling pathways in cell proliferation, invasion 
and migration, but there is limited relevant therapy targeting 
these signalling pathways. The evidence indicating the relation-
ship between PLC isoforms and breast cancer has suggested a 
possibility to develop target therapy for breast cancer. Some of 
the previous studies highlighted the alteration of PLC expres-
sion levels in breast tumour cells. For example, the expression 
level of PLC-γ1 is seen to be changed in breast cancer cells, 
with PLC-γ1 having a role in the regulation of cell migration by 
targeting EGFR (18,19). Furthermore, PLC-δ4 is upregulated 
in breast tumour cells, and its overexpression enhances cell 
proliferation in those breast cancer cells with lower oncoge-
nicity (20). It has been reported that a poor clinical outcome of 
breast tumour is associated with an increased expression level 
of PLC-β2, which appears to be a molecular marker indicating 
the severity of breast cancer. In addition, PLC-β2 provokes 
the transition from G0/G1 to S/G2/M cell cycle phase, which 
is important in cancer progression and inositol lipid-related 
modifications of the cytoskeleton architecture occurring 
during tumour cell division, motility and invasion (10). In vivo, 
dominant-negative PLC-γ1 fragment reduced the metastatic 
potential of breast cancer in transgenic mouse (21). Metastasis 
assays also demonstrated that nude mice with knockdown of 
PLC-γ1 presented inhibition of breast cancer-derived lung 
metastasis (8).
Based on a previous study, the aim of this work was to 
establish a correlation for the pattern of expression of 5 PLC 
isoforms (α, β, δ, ε, and γ) in human breast cancer tissues 
with clinical information (differentiation, tumour staging, 
histology type and clinical outcome). We demonstrated that 
mammary tissues widely expressed PLC-α, -β1, -δ, -ε, and -γ1. 
No significant difference in the levels of the different isozymes 
was seen between node positive and node negative tumours. 
Poorly differentiated breast tumours (grade 2 and grade 3) had 
significantly higher levels of PLC-γ1. Over a 10-year period, 
high levels of PLC-δ were significantly correlated with a 
shorter disease-free survival.
Materials and methods
Materials and reagents. A polyclonal antibody to human 
PLC-γ1 was purchased from Santa Cruz Biotechnology Ltd. 
(Santa Cruz, CA, uSA). RNA extraction kit and the first strand 
cDNA synthesis kit were from AbGene Laboratories (Surrey, 
uK). The master mix for conventional PCR and a customer 
quantitation PCR master mix for quantitative PCR were also 
purchased from AbGene Laboratories.
Breast cancer cell lines MCF-7 and MDA MB 231 were 
purchased from the European Collection of Animal Cell 
Cultures (ECACC, Salisbury, uK). Human umbilical vein endo-
thelial cells (HuvEC) were purchased from TCS Biologicals 
Ltd. (Oxford, uK). Breast cancer tissues (n=120) and normal 
background tissues (n=32) were collected immediately after 
surgery and stored at -20°C until use. Patients were routinely 
followed clinically after surgery. The median follow-up period 
was 72 months. The presence of tumour cells in the collected 
tissues was verified by examination of frozen sections using 
H&E staining by a consultant pathologist.
Tissue processing and extraction of RNA and generation of 
cDNA. Over 20 frozen sections from the each tissue sample 
were homogenised in an RNA extraction solution using a hand 
held homogeniser to extract total RNA. The concentration of 
RNA was quantified using a uv spectrophotometer. RNA 
(1 µg) was used to generate cDNA using a commercially avail-
able RT kit (AbGene Laboratories).
Detection of PLC isoforms using RT-PCR. Routine RT-PCR 
was carried out using a PCR master mix that was commercially 
available (AbGene). Primers were designed using the Beacon 
Designer software (version 2, CA, uSA) (17), to amplify 
regions of human PLC-γ1 that have no significant overlap with 
other known sequences and to ensure that the amplified prod-
ucts span over at least one intron. The primer sequences are 
given in Table I. β-actin was used as a housekeeping control. 
Reactions were carried out using the following conditions: 
94˚C for 5 min, 36 cycles of 94˚C for 15 sec, 55˚C for 25 sec 
and 72˚C for 15 sec. PCR products were separated on a 2% 
agarose gel and photographed using a digital camera mounted 
over a uv transluminator.
Quantitative analysis of the transcript of PLC isoforms. The 
level of PLC-γ1 transcripts from the prepared cDNA described 
above was determined using real-time quantitative PCR, based 
on Amplifluor™ technology that was modified from previous 
studies (18,19). In brief, pairs of PCR primers were designed 
using the Beacon Designer software (version 2), with one 
of the primers having an additional sequence, known as the 
Z sequence (5'-actgaacctgaccgtaca) which is complementary 
to the universal Z probe (Intergen Inc., Oxford, uK). A 
Taqman detection kit for β-actin was purchased from Perkin-
Elmer. The reaction was carried out using the following: 
Hot-start Q-master mix (Abgene), 10 pmol of the specific 
forward primer, 1 pmol of the reverse primer (which has the 
Z sequence), 10 pmol of FAM-tagged probe (Intergen Inc.), 
and cDNA transcribed from approximately 50 ng of RNA. 
The reaction was carried out using an iCycler iQTM (Bio-Rad) 
which equipped with an optic unit that allows real-time detec-
tion of 96 reactions, using the following condition: 94˚C for 
12 min, 100 cycles of 94˚C for 15 sec, 55˚C for 40 sec and 72˚C 
for 20 sec. The levels of the transcripts were generated from a 
standard that was simultaneously amplified with the samples.
Immunohistochemical staining of PLC-γ1 protein. The 
procedure was carried out as previously reported with minor 
modifications (19,20). Frozen sections of breast tumour and 
background tissue were cut at a thickness of 6 µm using a cryo-
stat. The sections were mounted on Superfrost Plus (Gerhard 
Menzel, Germany), microscope slides, air-dried and fixed in a 
mixture of 50% acetone and 50% methanol. The sections were 
then placed in ‘Optimax’ wash buffer for 5-10 min to rehydrate 
before being incubated for 20 min in a 0.6% BSA blocking 
solution and probed with the primary antibody. Following 
extensive washings, sections were incubated for 30 min in the 
secondary biotinylated antibody (Multilink Swine anti-goat/
mouse/rabbit immunoglobulin, Dako Inc.). Avidin Biotin 
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Complex (vector Laboratories, Nottingham, uK) was then 
applied to the sections followed by more extensive washings. 
Diaminobenzidine chromogen (vector Laboratories) was 
to the sections which were incubated in the dark for 5 min. 
Sections were then counter-stained in Gill's haematoxylin and 
dehydrated in ascending grades of methanol before clearing in 
xylene and mounting under a cover slip. Images were obtained 
using a digital camera.
Statistical analysis. Statistical analysis was carried out using 
Mann-Whitney u test and Kruskal-Wallis test. Survival 
analysis was performed using Kaplan-Meier survival and Cox 
proportional analysis.
Results
Expression of PLC isoforms in human breast cancer tissues. 
We first studied the levels of expression of the 5 PLC isoforms 
using quantitative analysis of the respective transcripts. As 
shown in Fig. 1A, PLC-α, -β1, -δ and -ε showed increased 
levels in tumour tissues compared with normal tissues. On 
the contrary, the expression level of PLC-γ1 in tumour tissues 
was lower than in normal tissues. Notably, statistical signifi-
cance was shown in PLC-β1 and PLC-ε transcript levels, with 
p=0.0325 and p=0.0252, respectively, which demonstrated the 
considerable differences in the expression levels of these two 
isoforms between breast cancer and normal tissues.
In addition to the quantitative analysis of transcript levels, 
we used an anti-PLC-γ1 as a case study to assess the protein 
expression and distribution in breast cancer. Immunochemical 
staining was performed for PLC-γ1 in a small number of 
frozen sections of the breast tumour tissue samples together 
with some adjacent background mammary tissues. As seen 
in Fig. 1B, normal mammary epithelial cells stained very 
strongly for the PLC, but little staining was present in normal 
stromal cells. However, in breast cancer, the pattern of staining 
varied from that of normal epithelial cells. As shown in Fig. 1B 
(right panel), breast cancer cells stained rather weakly for the 
protein, whereas stromal cells stained strongly.
Levels of PLCs and nodal status. With the aim to investigate 
whether the expression level of PLC is associated with lymph 
Figure 1. Levels of expression of PLC isoforms in non-neoplastic mammary tissues and breast cancer tissues. (A) PLC-α, -β1, -δ and -ε expression increased 
in tumour tissues compared with normal tissues, with statistical significance shown in PLC-β1 (p=0.0325) and PLC-ε (p=0.0252) levels. PLC-γ1 presented a 
reduced level in breast tumour tissues. (B) Expression of PLC-γ1 in human mammary tissues. Left panels: normal non-neoplastic tissues; right panels: breast 
cancer tissues. In normal tissues, PLC-γ1 is largely seen in the cytoplasm of epithelial cells. Neither stromal fibroblasts nor vascular endothelial cells showed 
positive staining. However, in breast cancer tissues, the stromal cells displayed a substantial amount of staining. In contrast, the breast cancer cells showed little 
positive staining, thus indicating a shift of staining pattern between stromal and epithelial/cancer cell staining.
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node status, cDNA samples from node-positive and node- 
negative breast tumour tissues were tested using real-time 
quantitative PCR. As shown in Fig. 2, node-positive tissues 
had lower PLC-β1, -δ, -γ1, and -ε levels, whilst higher PLC-α 
expression was shown. However, no statistically significant 
differences in the isoform levels were detected between the 
node-positive and node-negative breast tumour tissues.
Correlation of PLC levels with tumour grade and histology 
types. We examined PLC levels in breast tumours of different 
grades. As shown in Fig. 3A, grade 3 tumours had higher 
levels of PLC-β1, -γ1, -δ and -ε. Higher levels of PLC-α were 
detected in grade 1 tumours. A statistical difference was seen 
in PLC-γ1 expression between grade 1 and grade 2 (p=0.04), 
with the patients in grade 2 showing higher levels compared to 
those in grade 1.
When histology types were considered, there was a trend 
in ductal tumours to have higher levels of PLC-β1, -γ1, -δ and 
-ε, but lower levels of PLC-α (Fig. 3B). However, no statistical 
significance was found between these groups.
Levels of PLC in TNM stages. To evaluate the correlation 
between PLC levels and TNM stages, we quantified the levels 
of the different isoforms in breast tumours from TNM1 to 
TNM4. In particular, all the isoforms we examined presented 
the highest expression levels in TNM3 stage. There was also 
a significant difference in PLC-γ1 levels when comparing 
tumours of the different TNM stages (TNM1 versus TNM2 
Table I. PCR primers.
Gene Sense (5'-3') Antisense (5'-3')
PLC-α tagaactcacggacgacaa actgaacctgaccgtacacatactcaggtgcaagtctct
PLC-β1 gcaaaaagcaaaccatatct actgaacctgaccgtacagacttgctcttgttttggag
PLC-δ gttctccatcgaggacatt actgaacctgaccgtacacttgaagacaatggagaagc
PLC-ε ttgccaaagattctctcaat actgaacctgaccgtacacatgattttctcccaacatt
PLC-γ1 agaccttccaggtcaagc actgaacctgaccgtacagcggatctccttaatttca
β-actin atgatatcgccgcgctcg cgctcgtgtaggatcttca
Figure 2. Expression of PLC isoforms in node-negative and node-positive breast tumours. There is a trend for reduced level of PLC-β1, -γ1, -δ, and -ε in node-
positive tumour tissues in comparison with node-negative tumour tissues. Conversely, PLC-α presented an increased expression in node positive tumour tissues.
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p=0.021; TNM1 versus TNM4 p=0.022), with a decreased 
level in TNM2 and TNM4 in comparison with TNM1. The 
quantity of PLC-ε also reached statistical significance (TNM1 
versus TNM3 p=0.0265; TNM3 versus TNM4 p=0.002), and 
the result showed that patients in TNM1 and TNM4 had a 
markedly reduced level of PLC-ε expression compared with 
the patients in TNM3 stages (Fig. 4).
PLC expression and predicted prognosis. In order to establish 
if a link exists between the isoforms of PLC and the predicted 
clinical outcome at the time of operation, the Nottingham 
Prognostic Index was used as an indicator, where NPI <3.4 
was designated as NPI1, and comprised of patients who had 
a good prognosis. NPI2 and NPI3, with the value 3.4-5.4 and 
>5.4, respectively, had moderate and poor prognosis. As shown 
Figure 3. Expression of the PLC transcripts in different tumour grade and histological types. (A) PLC-β1, -γ1, -δ and -ε expression increased markedly in 
grade 3 breast tumour tissues (poorly differentiated). Higher levels of PLC-α was shown in grade 1 tumours (well differentiated). There is a reduction in 
PLC-γ1 expression levels detected in grade 1 tumour tissues compared to breast tumours in grade 2 (moderately differentiated) (p=0.04). (B) There is a trend 
in ductal tumours showing higher levels of PLC-β1, -γ1, -δ and -ε, but lower levels of PLC-α; however, there is no statistical significance between these groups.
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Figure 4. PLC isoforms in patients with different TNM tumours. Breast cancer patients in TNM3 showed an increased level of all PLC isoforms. The results 
show evidence of a relationship between PLC-γ1 and the different TNM stages, with a decreased level of PLC-γ1 seen in TNM2 and TNM4 in comparison 
with TNM1 (TNM1 versus TNM2 p=0.021; TNM1 versus TNM4 p=0.022); Statistically significant differences were also seen for expression levels of PLC-ε. 
(TNM1 versus TNM3 p=0.0265; TNM1 versus TNM4 p=0.002), with reduced level in TNM1 and TNM4 compared with TNM3.
Figure 5. Transcript levels of PLC isoforms in patients with predicted outcome, using the Nottingham Prognostic Index as an indicator. NPI1=NPI <3.4 (with 
good prognosis), NPI2=NPI 3.4-5.4 (with moderate prognosis), NPI3=NPI >5.4 (with poor prognosis). Levels of PLC isoforms appeared to be at lower levels 
in NPI3 tumours compared with NPI1 tumours, although differences were not statistically significant.
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in Fig. 5, all the isoforms appeared to be at lower levels in 
NPI3 tumours compared with NPI1 tumours. However, the 
results were not statistically significant.
PLC expression and clinical outcomes. To determine the 
correlation between PLC and clinical outcome, patients were 
divided into four groups: patients who remained disease-free, 
patients with metastasis, patients with local recurrence and 
patients who died from breast cancer. As shown in Fig. 6, 
after a 10-year follow up, patients who suffered from compli-
cations had low expression levels of PLC-α, -γ1 and -ε, but 
high levels of PLC-β1 and -δ. This was particularly evident 
when all the patients with complications were considered 
together. Moreover, the differences of expression between 
metastasis and recurrence tumour tissues in PLC-β1 level 
and PLC-δ level were statistically different (p=0.033 and 
p=0.025, respectively).
Levels of PLC and long-term survival. We assessed the asso-
ciation between PLC levels and breast cancer-related death 
using Kaplan-Meier survival analysis. An average transcript 
level of NPI2 group was set as a threshold. Higher levels of 
PLC-δ transcripts were associated with a shorter disease-free 
survival, but not for overall survival (Fig. 7). Patients with 
higher PLC-δ transcript level had an average disease-free 
survival of 96.7 months (95% confidence interval 67.7-124.4 
months) compared to 137.4 months (95% confidence 
interval 127.6-147.2 months) of patients who had lower expres-
sion of PLC-δ. No correlation with either overall survival or 
disease-free survival was observed for other PLC isozymes 
(data not shown).
Discussion
Globally, breast cancer is the most frequently diagnosed cancer 
and the leading cause of cancer death in women. Considerable 
evidence has suggested that diverse molecules can induce 
aberrant signalling events in breast cancer and lead to breast 
tumour proliferation, invasion, and migration. The recent 
identification of phospholipase C (PLC), a phospholipid-
hydrolyzing enzyme, has a role in the regulation of a number 
of cellular behaviours and promotes tumourigenesis by regu-
lating cell motility, transformation and cell growth, partly by 
acting as signalling intermediates for cytokines such as EGF 
and interleukins in cancer cells. A number of PLC isoforms 
have been investigated with studies focusing on their functions 
and expression profiles in human cancers, however, the impor-
tance of PLC in clinical diagnosis is largely unknown. Our 
study aimed to examine the pattern of expression of 5 PLC 
isoforms, namely, α, β, γ, δ and ε in human breast cancer, and 
to predict their correlation with clinical significance.
Oestrogen exposure is one of the risk factors for the devel-
opment of breast cancer (22). Ovarian hormones induce cell 
proliferation, and the uncorrected signal molecules result in 
Figure 6. Levels of expression of PLC in tumours from patients with different clinical outcomes after a 10 year follow-up: patients who remained disease-free, 
patients who developed metastasis, patients who developed local recurrence and those who died from breast cancer. Patients who died from other unrelated 
causes were excluded from the analysis. There was a statistically significant difference in PLC-β1 and PLC-δ levels between metastasis and recurrence tumour 
tissues (p=0.033 and p=0.025, respectively).
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the generation of malignant phenotypes (23). up to now, there 
have been limited studies focusing on the functions of PLC-α 
in breast cancer, but it has been reported that PLC-α is able 
to mediate the phosphatidylinositol (PI) second messenger 
pathway and the components in this pathway can increase 
some effects of estrogen (24). However, there needs to be 
further studies to investigate if there is a direct correlation 
between PLC-α and oestrogen.
The important factors for the prediction of clinical 
outcomes in breast cancer patients are tumour size, lymph 
node status and tumour grade, moreover, the involvement of 
molecular markers is beneficial to develop a treatment plan 
for patients with different tumour stages. Previous studies 
presented PLC-β2, an isoform of PLC family, as a potential 
marker to predict the malignancy of breast cancer, with 
upregulated expression levels being detected in different types 
of breast tumours (25). In addition, breast cancer cell lines 
with high invasive potential show higher expression levels of 
PLC-β2 in comparison with less-tumourigenic breast cancer 
cell lines (11). 
In the present study, we detected isoform of the PLC-β 
subfamily and showed that there is a significantly increased 
level of PLC-β1 in breast tumour tissues. Tissue microarray 
(TMA) analysis demonstrated a poor expression of PLC-β2 
in normal tissues and significantly higher expression levels 
in most tumour tissue specimens. Furthermore, there is no 
relationship between node status and PLC-β1 level in breast 
tumour tissues. This result was also verified in our study 
focused on PLC-β1. PLC-β2 expression closely correlated 
with tumour grading, with an increase of staining intensity 
from grade 1 to grade 3. Similarly, our study demonstrated 
that grade 3 tumours showed the highest expression levels of 
PLC-β1 (11). Lower overall survival has been demonstrated 
in patients whose primary tumours expressed high levels 
of PLC-β2. The above findings therefore indicate a strong 
correlation between PLC-β levels and poor prognosis of breast 
cancer. Moreover, our present study demonstrated a significant 
difference in PLC-β1 expression between metastasis and 
recurrence tumour tissues (p=0.033), which may indicate its 
role in promoting migration in breast cancer.
The expression of PLC, primarily PLC-γ, has been 
studied in a number of cancer types, although most of these 
studies have concentrated on established cell lines. In terms 
of clinical cancers, studies are available on squamous cell 
carcinoma, lung cancer, thyroid cancer, and limited on breast 
cancer (26-28). In a small-scale study in human breast cancer, 
PLC-γ was shown to be overexpressed in the majority of 
tumours in comparison with normal mammary tissues. The 
role of PLC in cells and indeed in cancer cells has been long 
studied. As already discussed, it seems that the prime role 
of the enzyme is the regulation of cell migration and adhe-
sion by acting downstream of a number of cellular signalling 
pathways (29).
The current study was unable to provide further details 
of the link between PLC-γ and its associated signalling 
complexes. Future studies would need to address these points. 
The relationship between the PLC isoforms and long-term 
survival for patients with breast tumours was examined here. 
Our observations are interesting and suggest that these PLC 
isoforms may be potential therapeutic targets. Therapeutic 
applications of PLC-γ have been studied. PLC-γ inhibitors 
have been shown to inhibit PLC-γ mediated cell function in 
cancer cells. For example, the PLC-γ inhibitor, u73122, is able 
to inhibit the activation of PLC-γ, and hence PLC-γ mediated 
cell migration and invasion in a number of cancer cell types. 
The inhibitor has also the potential of reducing the growth of 
mammary tumours in vivo (30).
The loss of PLC-δ expression is highly associated with 
its role as a tumour suppressor in esophageal squamous cell 
carcinoma (ESCC). The tumourigenic ability of ESCC cells 
is suppressed both in vitro and in vivo assays. PLC-δ has 
been suggested to have a significant role in ESCC metastasis 
since its downregulation has been shown to have a reduc-
tion in cell mobility and an increase in cell adhesion (16). In 
addition, decreased PLC-δ expression correlated with poor 
clinical outcome in patients with acute or chronic myeloid 
leukaemia (16). In our study, patients with tumour metas-
tasis expressed higher levels of PLC-δ than those with local 
recurrence. Significantly, breast cancer patients with higher 
expression levels of PLC-δ experience a shorter disease-free 
Figure 7. Association of PLC with long-term survival. Shown are the Kaplan-
Meier survival curves for PLC-δ.
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survival period, and this result might indicate a correlation 
between PLC-δ and recurrence for breast cancer patients.
Taken together, the findings of the current study demon-
strate for the first time that isoforms of PLC are aberrantly 
expressed in human breast cancer. The abnormalities are linked 
to both prognosis and to some degree to clinical outcomes. 
The study strongly indicated the potential therapeutic value 
of these signalling intermediates in human breast cancer and 
therefore warrants further investigation.
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